Walgreens weighs $2 bln sale of pharmacy automation unit - Bloomberg News
Adds response from Walgreens
Jan 25 (Reuters) -Pharmacy chain Walgreens Boots Alliance Inc WBA.O is weighing a sale of its pharmacy automation business, which could fetch up to $2 billion, Bloomberg News reported on Wednesday citing people familiar with the matter.
Walgreens will prepare for the start of Automation Unit iA's sale process around next month, the report said according to sources who asked not to be identified as the matter is private.
The unit, which helps pharmacies fill prescriptions, could also draw interest from other rival healthcare companies, the report said, adding that no final decision had been made and the drugstore chain could choose to keep the business.
Walgreens declined to comment on the report.
The potential sale comes at a time when the company, one of the largest U.S. pharmacies, has been looking to gain a bigger foothold in the healthcare space, with sales at its traditional brick-and-mortar stores hit by lower demand for COVID vaccines and testing compared to last year's peak.
Reporting by Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.